Click for best price
Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, Share 2024
The global Gastroesophageal Junction Adenocarcinoma Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Drug Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Gastroesophageal Junction Adenocarcinoma Therapeutics include Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly and FivePrime Therapeutics, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.
This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Junction Adenocarcinoma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Junction Adenocarcinoma Therapeutics. This report contains market size and forecasts of Gastroesophageal Junction Adenocarcinoma Therapeutics in global, including the following market information:
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Gastroesophageal Junction Adenocarcinoma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Segment Percentages, by Type, 2023 (%)
Drug
Surgery
Chemotherapy
Targeted Therapy
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Segment Percentages, by Application, 2023 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gastroesophageal Junction Adenocarcinoma Therapeutics revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Gastroesophageal Junction Adenocarcinoma Therapeutics revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharmaceuticals
AstraZeneca
Bayer
Beigene
Bristol-Myers Squibb
Daichii Sankyo
Elevar Therapeutics
Eli Lilly
FivePrime Therapeutics
Incyte
Macrogenics
Merck Co
Ono Pharmaceuticals
Roche
Taiho Pharmaceuticals
Zai Labs
ZymeWorks
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gastroesophageal Junction Adenocarcinoma Therapeutics, market overview.
Chapter 2: Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Gastroesophageal Junction Adenocarcinoma Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastroesophageal Junction Adenocarcinoma Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
109 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Overall Market Size
2.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size: 2023 VS 2030
2.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players in Global Market
3.2 Top Global Gastroesophageal Junction Adenocarcinoma Therapeutics Companies Ranked by Revenue
3.3 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies in Global Market, by Revenue in 2023
3.5 Global Companies Gastroesophageal Junction Adenocarcinoma Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gastroesophageal Junction Adenocarcinoma Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size Markets, 2023 & 2030
4.1.2 Drug
4.1.3 Surgery
4.1.4 Chemotherapy
4.1.5 Targeted Therapy
4.2 By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2024
4.2.2 By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2025-2030
4.2.3 By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2023 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.2 By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2024
5.2.2 By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2025-2030
5.2.3 By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2023 & 2030
6.2 By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2024
6.2.2 By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2025-2030
6.2.3 By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030
6.3.2 US Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.3.3 Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.3.4 Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030
6.4.2 Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.3 France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.4 U.K. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.5 Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.6 Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.7 Nordic Countries Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.4.8 Benelux Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030
6.5.2 China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.5.3 Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.5.4 South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.5.5 Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.5.6 India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030
6.6.2 Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.6.3 Argentina Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030
6.7.2 Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.7.3 Israel Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.7.4 Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
6.7.5 UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size, 2019-2030
7 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies Profiles
7.1 Astellas Pharmaceuticals
7.1.1 Astellas Pharmaceuticals Company Summary
7.1.2 Astellas Pharmaceuticals Business Overview
7.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.1.4 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.1.5 Astellas Pharmaceuticals Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.2.4 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.3.4 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.3.5 Bayer Key News & Latest Developments
7.4 Beigene
7.4.1 Beigene Company Summary
7.4.2 Beigene Business Overview
7.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.4.4 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.4.5 Beigene Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.5.4 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Daichii Sankyo
7.6.1 Daichii Sankyo Company Summary
7.6.2 Daichii Sankyo Business Overview
7.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.6.4 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.6.5 Daichii Sankyo Key News & Latest Developments
7.7 Elevar Therapeutics
7.7.1 Elevar Therapeutics Company Summary
7.7.2 Elevar Therapeutics Business Overview
7.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.7.4 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.7.5 Elevar Therapeutics Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.8.4 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 FivePrime Therapeutics
7.9.1 FivePrime Therapeutics Company Summary
7.9.2 FivePrime Therapeutics Business Overview
7.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.9.4 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.9.5 FivePrime Therapeutics Key News & Latest Developments
7.10 Incyte
7.10.1 Incyte Company Summary
7.10.2 Incyte Business Overview
7.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.10.4 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.10.5 Incyte Key News & Latest Developments
7.11 Macrogenics
7.11.1 Macrogenics Company Summary
7.11.2 Macrogenics Business Overview
7.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.11.4 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.11.5 Macrogenics Key News & Latest Developments
7.12 Merck Co
7.12.1 Merck Co Company Summary
7.12.2 Merck Co Business Overview
7.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.12.4 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.12.5 Merck Co Key News & Latest Developments
7.13 Ono Pharmaceuticals
7.13.1 Ono Pharmaceuticals Company Summary
7.13.2 Ono Pharmaceuticals Business Overview
7.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.13.4 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.13.5 Ono Pharmaceuticals Key News & Latest Developments
7.14 Roche
7.14.1 Roche Company Summary
7.14.2 Roche Business Overview
7.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.14.4 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.14.5 Roche Key News & Latest Developments
7.15 Taiho Pharmaceuticals
7.15.1 Taiho Pharmaceuticals Company Summary
7.15.2 Taiho Pharmaceuticals Business Overview
7.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.15.4 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.15.5 Taiho Pharmaceuticals Key News & Latest Developments
7.16 Zai Labs
7.16.1 Zai Labs Company Summary
7.16.2 Zai Labs Business Overview
7.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.16.4 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.16.5 Zai Labs Key News & Latest Developments
7.17 ZymeWorks
7.17.1 ZymeWorks Company Summary
7.17.2 ZymeWorks Business Overview
7.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Major Product Offerings
7.17.4 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global Market (2019-2024)
7.17.5 ZymeWorks Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Opportunities & Trends in Global Market
Table 2. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers in Global Market
Table 3. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints in Global Market
Table 4. Key Players of Gastroesophageal Junction Adenocarcinoma Therapeutics in Global Market
Table 5. Top Gastroesophageal Junction Adenocarcinoma Therapeutics Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Share by Companies, 2019-2024
Table 8. Global Companies Gastroesophageal Junction Adenocarcinoma Therapeutics Product Type
Table 9. List of Global Tier 1 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gastroesophageal Junction Adenocarcinoma Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2025-2030
Table 30. Astellas Pharmaceuticals Company Summary
Table 31. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 32. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 33. Astellas Pharmaceuticals Key News & Latest Developments
Table 34. AstraZeneca Company Summary
Table 35. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 36. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 37. AstraZeneca Key News & Latest Developments
Table 38. Bayer Company Summary
Table 39. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 40. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 41. Bayer Key News & Latest Developments
Table 42. Beigene Company Summary
Table 43. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 44. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 45. Beigene Key News & Latest Developments
Table 46. Bristol-Myers Squibb Company Summary
Table 47. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 48. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 49. Bristol-Myers Squibb Key News & Latest Developments
Table 50. Daichii Sankyo Company Summary
Table 51. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 52. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 53. Daichii Sankyo Key News & Latest Developments
Table 54. Elevar Therapeutics Company Summary
Table 55. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 56. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 57. Elevar Therapeutics Key News & Latest Developments
Table 58. Eli Lilly Company Summary
Table 59. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 60. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 61. Eli Lilly Key News & Latest Developments
Table 62. FivePrime Therapeutics Company Summary
Table 63. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 64. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 65. FivePrime Therapeutics Key News & Latest Developments
Table 66. Incyte Company Summary
Table 67. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 68. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 69. Incyte Key News & Latest Developments
Table 70. Macrogenics Company Summary
Table 71. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 72. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 73. Macrogenics Key News & Latest Developments
Table 74. Merck Co Company Summary
Table 75. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 76. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 77. Merck Co Key News & Latest Developments
Table 78. Ono Pharmaceuticals Company Summary
Table 79. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 80. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 81. Ono Pharmaceuticals Key News & Latest Developments
Table 82. Roche Company Summary
Table 83. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 84. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 85. Roche Key News & Latest Developments
Table 86. Taiho Pharmaceuticals Company Summary
Table 87. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 88. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 89. Taiho Pharmaceuticals Key News & Latest Developments
Table 90. Zai Labs Company Summary
Table 91. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 92. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 93. Zai Labs Key News & Latest Developments
Table 94. ZymeWorks Company Summary
Table 95. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product Offerings
Table 96. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 97. ZymeWorks Key News & Latest Developments
List of Figures
Figure 1. Gastroesophageal Junction Adenocarcinoma Therapeutics Segment by Type in 2023
Figure 2. Gastroesophageal Junction Adenocarcinoma Therapeutics Segment by Application in 2023
Figure 3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue in 2023
Figure 8. By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 9. By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 10. By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 12. By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 14. By Region - Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 15. By Country - North America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 16. US Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 20. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 21. France Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 28. China Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 32. India Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 34. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Market Share, 2019-2030
Figure 37. Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 41. Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
